View printer-friendly version

Download PDF

Emergent BioSolutions to Present at JPMorgan Healthcare Conference

GAITHERSBURG, Md.–(BUSINESS WIRE)–Dec. 21, 2006–Emergent BioSolutions Inc. (NYSE: EBS) today announced that it will present at the 25th Annual JPMorgan Healthcare Conference in San Francisco. Fuad El-Hibri, president, chief executive officer and chairman of the board of directors of Emergent BioSolutions will provide a company overview and outline future growth opportunities at 3:00 pm PST, Monday, January 08, 2007 at the St. Francis Hotel in San Francisco, California.

A webcast of the presentation will be available both live and by replay. To access both the live and archived webcast, please go to www.emergentbiosolutions.com, click on the “Investors” link and proceed to the “Webcasts & Presentations” section. The archived replay will be available 24 hours after the live presentation and will be accessible for 30 days.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of immunobiotics. Immunobiotics are vaccines and immune globulins that induce or assist the body’s immune system to prevent or treat disease. The company’s biodefense business is focused on developing and commercializing immunobiotics for use against biological agents that are potential weapons of bioterrorism. The company’s commercial business is focused on developing immunobiotics for use against infectious diseases with significant unmet or underserved medical needs. More information on the company is available at www.emergentbiosolutions.com.